Bio-Thera Solutions, Ltd. 688177.SS Stock

Bio-Thera Solutions, Ltd., commercial-stage biopharmaceutical company, researches and develops therapeutics for the treatment of cancer, autoimmune, cardiovascular, and other serious medical conditions. It offers QLETLI for treatment of ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn's disease, and uveitis; and POBEVCY to treat patients with metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, persistent, recurrent, and metastatic cervical cancer. The company also develops BAT1806, a tocilizumab biosimilar candidate of Actemra/RoActemra, which is in Phase III clinical trial; BAT2206, a biosimilar drug candidate used to treat psoriasis, Crohn's disease, and ulcerative colitis; BAT2306 to treat plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis; and BAT4406, BAT2606, and BAT2406 for treatment of various autoimmune diseases. In addition, it develops BAT4306F, BAT1308, BAT1006, BAT4706, BAT6026, BAT6005, BAT6021, BAT7104, BAT8006, BAT8009, BAT8010, BAT8008, and BAT8007 for treatment of oncology; BAT2094 and BAT6024 to treat cardiovascular diseases; BAT5906 that is in Phase II clinical trial for the treatment for wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions; and BAT2022 to treat infectious diseases. The company was founded in 2003 and is headquartered in Guangzhou, China.